Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9453.125 | 1.0087 | 1.0141 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9453.125 | 1.0040 | 1.0065 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9453.125 | 0.9775 | 0.9635 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9453.125 | 0.9661 | 0.9449 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9453.125 | 1.0023 | 1.0038 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9453.125 | 0.9833 | 0.9729 | 1.2351 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 9469.026 | 1.0066 | 1.0109 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 9469.026 | 0.9667 | 0.9448 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 9469.026 | 1.0353 | 1.0581 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 9469.026 | 0.9955 | 0.9925 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 9469.026 | 0.9767 | 0.9613 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 9469.026 | 1.0065 | 1.0107 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 9469.026 | 0.9642 | 0.9406 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 9469.026 | 0.9712 | 0.9522 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 9469.026 | 0.9307 | 0.8847 | 1.2092 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 10268.122 | 1.5205 | 2.8710 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00000877 | uM | 10268.122 | 1.2264 | 1.7587 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0000438 | uM | 10268.122 | 1.5203 | 2.8701 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.000219 | uM | 10268.122 | 1.1429 | 1.4687 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0011 | uM | 10268.122 | 1.2240 | 1.7501 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.00548 | uM | 10268.122 | 1.1209 | 1.3940 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.0274 | uM | 10268.122 | 0.9708 | 0.9089 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.137 | uM | 10268.122 | 1.0483 | 1.1544 | 0.6345 | |
| HCC38 | TNBC | Basal B | Cetuximab | EGFR | ErbB | 0.685 | uM | 10268.122 | 0.9228 | 0.7620 | 0.6345 | |
| HCC70 | TNBC | Basal A | Cetuximab | EGFR | ErbB | 0.00000175 | uM | 7856.018 | 1.0401 | 1.0856 | 0.9388 |